Ji HB, Chen ZH. Clinical effects of stereotactic radiotherapy combined with gemcitabine in treatment of locally advanced pancreatic carcinoma.
Shijie Huaren Xiaohua Zazhi 2015;
23:5882-5888. [DOI:
10.11569/wcjd.v23.i36.5882]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To evaluate the clinical effects of stereotactic conformal radiotherapy combined with gemcitabine in patients with locally advanced pancreatic carcinoma.
METHODS: A total of 118 patients with unresectable locally advanced pancreatic carcinoma were divided into two groups to receive either radiotherapy combined with gemcitabine (group A, 56 cases) or radiotherapy alone (group B, 62 cases). The standard dose of stereotactic conformal radiotherapy prescribed was 35-45 Gy to the 50%-65% isodose curve. The total dose was delivered over 10-13 d with a fraction dose of 2.8-3.5 Gy and 6 fractions per week. Concomitant chemotherapy started at the first day of radiotherapy: gemcitabine at a dose of 600 mg/m2 was given on days 1 and 8, and adjuvant chemotherapy was administered three weeks after radiotherapy at a dose of gemcitabine 1000 mg/m2 on days 1 and 8, 21 days per cycle, for 4-6 cycles continuously.
RESULTS: The patients underwent CT or MR examination 2 mo after 2 treatment. The tumor response rate of group A was 67.8% (38/56). Median survival time was 12.8 mo (range, 4-70 mo). The overall 1-year and 2-year survival rates were 58.9% (33/56) and 28.6% (16/56), respectively. Main side effects included leukopenia, thrombocytopenia, nausea and vomiting. The tumor response rate of group B was 30.6% (19/62). Median survival time was 8.5 mo (range, 5-56 mo). The overall 1-year and 2-year survival rates were 33.9% (21/66) and 12.9% (8/62), respectively. Main side effects were leukopenia and thrombocytopenia. Both the short-term and long-term therapeutic effects were better in the combination group than in the radiotherapy alone group.
CONCLUSION: Gemcitabine combined with stereotactic conformal radiotherapy is effective and safe in the treatment of patients with locally advanced pancreatic carcinoma.
Collapse